Sino and AstraZeneca sign licence agreement for TQC3721
Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca.
Drug Development
Evogene and Tel Aviv University launch drug discovery initiative
FDA grants rare paediatric designation to Vanda’s CMT2S therapy
Biocytogen and Whitehawk partner to develop ADCs
Vertex signs agreement to acquire Crinetics for $10bn
EC approves AbbVie’s Tepkinly combination for follicular lymphoma
Novartis to acquire Myricx Bio in up to $1.5bn deal
Besins Healthcare boosts drug delivery portfolio with UniD deal
